

## **Enrollment Form**

Phone: 844-NEX-4321 (844-639-4321) • Fax: 844-232-2618

## TO GET STARTED, COMPLETE THE ENROLLMENT FORM AND FAX IT TO 844-232-2618.

| PLEASE CHECK ALL BOXESTHAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM  |  |  |  |  |
|---|--|--|--|--|
| Patient Benefit Investigation Prescription Order  |  |  |  |  |
| SPECIALTY PHARMACY ORDE   | R FOR ASSIGNMENT OF BENEFITS ONLY:   |  |  |  |
| Please select <b>one</b> fulfillment option to indicate your preference. Note the Accredo Pharmacy AllianceRx Walgreens Prime CVS Health Pharmacy Humana Specialty Pharmacy | nat some insurers may require use of a particular specialty pharmacy.  ASPN Pharmacies, LLC  Cigna Specialty Pharmacy Services  Magellan Rx Pharmacy |  |  |  |
| PATIENT INFORMATION   |  |  |  |  |
| Last Name:  | First Name: MI:  |  |  |  |
| Date of Birth:  | Primary Language:  |  |  |  |
| Address:  |  |  |  |  |
| Phone: H  | ome Cell Email:  |  |  |  |
| Special Instructions:   |  |  |  |  |
| Current Medications:  |  |  |  |  |
| INSURANCE INFORMATION   |  |  |  |  |
| PLEASE COMPLETE ALL THAT APPLY AND <b>INCLUDE A FRONT AND BACK COPY OF INSURANCE CARD</b> FOR EACH TYPE OF INSURANCE  |  |  |  |  |
| Patient has no insurance and/or does not want insurance billed. Requests for Self Pay option available at preferred Specialty Pharmacy.                                     |  |  |  |  |
| Prescription Drug Card  | Medical Insurance  |  |  |  |
| Plan Name:  | Plan Name:   |  |  |  |
| Payer Phone: BIN:   | Payer Phone:   |  |  |  |
| PCN: Policy #: Group #:   | Policy #: Group #:   |  |  |  |
| Policy Holder Information (If different from patient)   | Policy Holder Information (If different from patient)  |  |  |  |
| Name:   |  |  |  |  |
| Date of Birth:  |  |  |  |  |
| Employer:   |  |  |  |  |
| Relationship to Patient:  | Relationship to Patient:   |  |  |  |

## PATIENT AUTHORIZATION (REQUIRED if "Prescription Order" has been requested above)

I understand that in order for Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc., and Lash (the company that will conduct reimbursement services on behalf of Merck) to provide me with assistance, Lash and its administrators (collectively, "Lash") will need to obtain, review, use, and disclose my personal health information related to my treatment with NEXPLANON, information on my request form,

## **PATIENT AUTHORIZATION** (continued)

and any prescription for NEXPLANON® (etonogestrel implant) (my "PHI"). I authorize my physician, pharmacy(ies), and my health plan(s) to disclose my PHI to Lash as necessary to complete the insurance investigation process. I further authorize Lash and the Specialty Pharmacies (Accredo Pharmacy, AllianceRx Walgreens Prime, ASPN Pharmacies, LLC, Cigna Specialty Pharmacy Services, CVS Health Pharmacy, Humana Specialty Pharmacy, or Magellan Rx Pharmacy) and their respective affiliates to exchange my PHI to provide support and to disclose the information to my health plan(s) and their contractors for the purpose of coordination of benefits, reimbursement support, investigating insurance coverage and coordination of the delivery, receipt and storage of my prescription medication for NEXPLANON for the sole purpose of administration to me by my prescribing provider named above. I authorize the Specialty Pharmacy to use my PHI to contact me via mail, telephone, text, or email in connection with information related to this Enrollment Form. In order for the Specialty Pharmacy to ship my prescription medication for NEXPLANON directly to my prescribing provider, I authorize the Specialty Pharmacy to communicate with my prescribing provider about my PHI in order to coordinate the delivery, receipt, and storage of my prescription medication for NEXPLANON for the sole purpose of administration of my prescribing provider at my next scheduled appointment. I understand that my PHI disclosed pursuant to this Authorization may no longer be protected by certain federal privacy laws and may be re-disclosed by the recipient, but that Lash has agreed to use my PHI only for the purposes described herein.

I understand that if I do not sign this Authorization, that will not affect my receipt of treatment (including with NEXPLANON) or of health insurance benefits, but that I will not be able to obtain certain assistance provided by Lash on behalf of Merck. I understand that I may cancel this Authorization at any time by mailing a written request for such cancellation to Lash, PO Box 741, Monroeville, PA, 15146-0741. I understand that canceling my Authorization will not affect uses and disclosures of PHI already made in reliance on the Authorization before my cancellation is received by Lash.

If I do not cancel this Authorization, the Authorization will expire 12 months from the date signed below. Merck has retained Lash and the Specialty Pharmacies to provide support to customers, including reimbursement support. Information and questions related to the information provided in regard to this request should be referred directly to Lash. Merck personnel are not aware of patient-specific reimbursement information and are not permitted to discuss such information with customers. I have read this document or have had it explained to me. I understand that I may request a copy of this Authorization once it has been signed.

| Patient Signature:  | Date:                              |
|---|------------------------------------|
| Print Name:   | Date:                              |
| Relationship to patient if signing on their behalf:   | Date:                              |
| If you have questions about completing this form or need ad 844-NEX-4321 (844-639-4321). Thank you. | lditional information, please call |

| Patient name:  |  |  |                           |
|--|--|--|---------------------------|
| PRESCRIPTION INFORMATION (REQUIRED if "Prescription Order" has been requested)   |  |  |                           |
| Dispense: 1 Rx NEXPLANON® (etonogestrel implant) 68 mg   | Days supplied: <u>3</u>  | years Refills: <u>0</u> Allergies:   |                           |
| SIG: To be inserted one time by prescriber subdermally   | Date of Last Mens  | es:  | _                         |
| Anticipated Insertion Date:  |  |  |                           |
| Product Substitution Permitted (Signature)   | Date   | Dispense as Written (Signature)  | Date                      |
| I certify that I have completed train  | ning for NEXPLANO  | N. If not certified, please contact your sales   | representative.           |
| PRESCRIBER INFORMATION (prescri  |  |  |                           |
| Office Contact:  | Phone  | e: Fa  | IX:                       |
| Address:   |  | City:  |                           |
| State: Zip Code: Tax ID #:   |  | State Medical License #:   |                           |
| NPI #:   |  |  | Contact Preference: Phone |
| Please indicate the diagnosis code(s): Z30.017   | Z30.46   | Other:   |                           |
| For ARNP, NP & PA, and other, collaborative physician agreement is with:   |  | NPI #:   | Date:                     |
| PRESCRIBER AUTHORIZATION   |  |  |                           |
| MUST CONTAIN ORIGINAL SIGNATURE  • This request has been prepared exclusively by the physician or physician of request ("my Practice").  • My Practice has obtained written authorization from the patient identified i disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the informatic Enrollment Form, as well as the information included in this request, to the Center for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Corsubsidiary of Merck & Co., Inc., the administrators of the Program, including other affiliates, and for the CSCN to use and disclose the information for the benefits investigation and reimbursement support. | in this request to<br>on relating to the<br>on disclosed in this<br>Customer Support<br>rp. ("Merck"), a<br>g their contractors or | of benefit claims, the specialty pharmacy mollection of applicable co-pay. I understand contacted.  I understand that information concerning prostatistical or other purposes and provided to lunderstand that the Program reserves the records to verify the information provided h |                           |

- My Practice has provided the patient identified in this request with the notices necessary to comply with all federal and state laws and regulations relating to medical and/or health privacy, including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Parts 160 and 164, as amended from time to time.
- If my patient is a minor, I certify that either 1) this patient's parent or guardian has consented to the patient's treatment with NEXPLANON (as allowable under the law of the state in which I practice), or 2) I, or a physician in my Practice, have determined that this patient has the capacity to consent to treatment with NEXPLANON under the law of the state in which I practice (and that consent of a parent or guardian is not required).
- I certify that I am authorized, pursuant to the laws of my state of licensure, to prescribe NEXPLANON.
- NOTICE: In the event that my patient's insurer provides coverage via an assignment of benefits, I understand that this Enrollment Form may also serve as a prescription that can, at my request, be forwarded to the relevant specialty pharmacy. However, I understand that prescribing and dispensing laws and regulations vary by state and that this form may NOT be consistent with the requirements (e.g., content or format) for a valid prescription in my state, in which case I am responsible for submitting a prescription to the relevant specialty pharmacy (or for including such form with this Enrollment Form) in a manner and on a form consistent with the

- I consent to receive communications related to the CSCN by telephone, email, and/or fax.
- . I verify that the information provided is complete and accurate to the best of my knowledge.
- I acknowledge the following: Merck has retained Lash, a subsidiary of AmerisourceBergen, a supplier of reimbursement support, to support the CSCN. Information and questions related to the information provided in response to the submission of this form should be referred directly to Lash. Merck personnel are not aware of patient coverage information and are not permitted to discuss such information with customers. Communications in response to this form will be prepared for me by Lash, providing reimbursement assistance services for Merck products pursuant to an agreement with Merck, in response to my request for insurance coverage information regarding my patient. The information provided will be based on statements of individuals not affiliated with Lash, the CSCN, or Merck. Neither Lash, the CSCN, nor Merck make any warranties, expressed or implied, about the accuracy of this information. Insurance coverage status can change over time based on a variety of factors, including processing of additional claims that impact deductibles and/or coverage limits, changes in benefit design, and a patient's change in insurance carrier. Any coverage information provided to me in response to this request is intended for my and my patient's reference only and does not guarantee current or future coverage for any Merck product. Individual patient coverage information is provided to the extent that information is made available by the insurance plan.

| Prescriber original signature: | Date: |  |  |
|--------------------------------|-------|--|--|
| • • •                          |       |  |  |
| Prescriber (please print):     |       |  |  |

To report an adverse event for a specific Merck product, including death due to any cause, please contact the Merck National Service Center at 800-444-2080.

**CUSTOMER SUPPORT CENTER** PHONE: 844-NEX-4321 (844-639-4321) • FAX: 844-232-2618

